This product, the USP 35–NF 30, is current from May 1, 2012 through July 31, 2012, as described below.
SIX-MONTH IMPLEMENTATION GUIDELINE
The United States Pharmacopeia–National Formulary and its supplements become official six months after being released to the public. The USP–NF, which is released on November 1 of each year, becomes official on May 1 of the following year. This six-month implementation timing gives users more time to bring their methods and procedures into compliance with new and revised USP–NF requirements.
The table below describes the official dates of the USP–NF and its supplements. The 2010 USP 34–NF 29, and its supplements, Interim Revision Announcements (IRAs) and Revision Bulletins to that edition, will be official until May 1, 2012, at which time the USP 35–NF 30 becomes official.
Publication Release Date Official Date Official Until
USP 35–NF 30 November 1, 2011 May 1, 2012 May 1, 2013 (except as superseded by supplements, IRAs, and
Revision Bulletins)
First Supplement to the
USP 35–NF 30		 February 1, 2012 August 1, 2012 May 1, 2013 (except as superseded by Second Supplement, IRAs,
and Revision Bulletins)
Second Supplement to the
USP 35–NF 30		 June 1, 2012 December 1, 2012 May 1, 2013 (except as superseded by IRAs and Revision Bulletins)
USP 36–NF 31 November 1, 2012 May 1, 2013 May 1, 2014 (except as superseded by supplements, IRAs, and
Revision Bulletins)
The table below gives the details of the IRAs that will apply to USP 35–NF 30.
IRA PF Posting Date Comment Due Date IRA Posting Date IRA Official Date
38(1) January 2, 2012 March 31, 2012 May 25, 2012 July 1, 2012
38(2) March 1, 2012 May 31, 2012 July 27, 2012 September 1, 2012
38(3) May 1, 2012 July 31, 2012 September 28, 2012 November 1, 2012
38(4) July 2, 2012 September 30, 2012 November 30, 2012 January 1, 2013
38(5) September 4, 2012 November 30, 2012 January 25, 2013 March 1, 2013
38(6) November 1, 2012 January 31, 2013 March 29, 2013 May 1, 2013
Revision Bulletins published on the USP website become official on the date specificed in the Revision Bulletin.

NOTICE AND WARNING
Concerning U.S. Patent or Trademark Rights—The inclusion in The United States Pharmacopeia or in the National Formulary of a monograph on any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner.
Concerning Use of USP or NF Text—Attention is called to the fact that USP and NF text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Secretary of the USPC Board of Trustees.
Copyright © 2011 The United States Pharmacopeial Convention 12601 Twinbrook Parkway, Rockville, MD 20852
All rights reserved.
ISSN: 1930-2932
ISBN: 978-1-936424-01-6
Printed in the United States by United Book Press, Inc., Baltimore, MD